Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 4

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 4
---
ificant Subsequent Events)                                               |     | 22 |
| [Financial Appendix]                                                          |     |    |

<div align='center'>1</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Three-month

Period Ended June 30, 2025 (Consolidated)

1. Financial Highlights for the Three-month Period Ended June 30, 2025

### (1) Business Performance
(i) Consolidated Financial Results (April 1 to June 30, 2025)

|                                                                                  |     |            |     |         |     |           |     |         |     |          |     |        |     |       |   |     |     |       | Billion JPY or percentage |
|                                                                                  |     | FY2024 Q1  |     |         |     | FY2025 Q1 |     |         |     | AER      |     |        |     |       |   | CER |     |       |                           |
|                                                                                  |     | JPY Change |     |         |     | % Change  |     |         |     | % Change |     |        |     |       |   |     |     |       |                           |
| Revenue                                                                          |     |            |     | 1,208.0 |     |           |     | 1,106.7 |     |          |     | -101.3 |     |  -8.4 | % |     |     |  -3.7 | %                         |
| Cost of sales                                                                    |     |            |     |  -387.0 |     |           |     |  -384.7 |     |          |     |    2.3 |     |  -0.6 | % |     |     |   4.3 | %                         |
| Selling, general and administrative expenses                                     |     |            |     |  -270.0 |     |           |     |  -255.9 |     |          |     |   14.1 |     |  -5.2 | % |     |     |  -0.0 | %                         |
| Research and development expenses                                                |     |            |     |  -168.5 |     |           |     |  -143.9 |     |          |     |   24.6 |     | -14.6 | % |     |